LOGIN  |  REGISTER
Astria Therapeutics
Terns Pharmaceuticals

Inari Medical to Present at the Bank of America 2023 Healthcare Conference

May 02, 2023 | Last Trade: US$79.97 0.00 0.00

IRVINE, Calif., May 02, 2023 (GLOBE NEWSWIRE) --  Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that its management team will present at the Bank of America 2023 Healthcare Conference on Tuesday, May 9, 2023 at 3:00 p.m. Pacific Time at the Encore Hotel in Las Vegas.

A live audio webcast and replay of the presentation may be accessed for 90 days on the “Investor Relations” section of the company’s website at: https://www.inarimedical.com/.

About Inari Medical, Inc.

Patients first. No small plans. Take care of each other. These are the guiding principles that form the ethos of Inari Medical. We are committed to improving lives in extraordinary ways by creating innovative solutions for both unmet and underrecognized health needs. In addition to our purpose-built products, we leverage our capabilities in education, clinical research, and program development to improve patient outcomes. We are passionate about our mission to establish our treatments as the standard of care for venous thromboembolism and beyond. We are just getting started.

Investor Contact:
ICR Westwicke
Caroline Corner
Phone +1-415-202-5678
This email address is being protected from spambots. You need JavaScript enabled to view it.

Terns Pharmaceuticals

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page